Business Context and Reporting Period
This Form 8-K is a current report filed by Obalon Therapeutics, Inc. (not Vyome Holdings, Inc.) on August 2, 2018. The registrant is a Delaware corporation and has elected to be treated as an emerging growth company. The report primarily addresses a change in executive leadership.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance rather than financial performance.
Material Changes
The material change reported is the appointment of Kelly Huang, Ph.D., to the position of President, effective August 2, 2018. Dr. Huang will serve in this role in addition to his existing position as Chief Operating Officer. Prior to this appointment, he held roles at Galderma, Spindletop Capital, Sensei Engage, Intrexon Corporation, and Endo Pharmaceuticals.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on future performance, or discussion of specific risks and contingencies. The document includes a press release (Exhibit 99.1) announcing the appointment.
Investor Verification Checklist
- Verify the exact scope of Dr. Huang's new responsibilities as President alongside his COO duties.
- Review the attached press release (Exhibit 99.1) for additional context on the leadership transition.
- Confirm the company's status as an emerging growth company and any associated reporting exemptions.
- Note that this filing does not contain updated financial data; refer to the most recent 10-Q or 10-K for financial metrics.